Axogen Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
We can kick it off. Good afternoon, and welcome to the Jefferies Global Healthcare Conference in London. My name is Mike Sarcone. I am an analyst on the U.S. Medical Supplies and Devices team, and this is the session for AxoGen. And with us from the company, we have Mike Dale, CEO, and Lindsey Hartley, CFO. Mike, Lindsey, thank you for joining us.
Our pleasure. Thank you. I guess just to kick off, Mike, for those in the audience who are less familiar with the story, maybe can you give us a brief overview of the company's mission and value proposition in the marketplace?
Then just to level set the conversation, talk about key strategic priorities as we exit this year and head into 2027.
Certainly. AxoGen is dedicated to peripheral nerve restoration. Our literal mission is to restore health and improve quality of life by making the restoration of peripheral nerve function an expected standard of care. Starting with that really begets and describes our work every day. Now, your peripheral nerve function, for those who just haven't thought about it, because it's something you take for granted, is your sensory function and your motor function. Your whole body is essentially reflecting those functions. When those are disturbed through either disease or injury or iatrogenic side effect interventions for treating some other problem, for the most part, those defects are not treated. There's a lot of reason for that, historically.
One, a lack of treatment options that were available, or only the ability to use an autograft, basically harvesting a nerve from somewhere else on the body and using that as a substitute. This is a situation which crosses all types of healthcare situations and different specialties. AxoGen, in terms of our work product, is about making the restoration of those functions an expectation. Strategically, the priorities we've set for doing that were the product of a traditional strategic planning process exercise to understand how we could make progress on that in the most effective, efficient way, which is what obviously those processes are about. For us, as a public company, it was about setting a platform of expectations and doing so very publicly for all stakeholders.
One was growth, and that was, we believed that looking at the opportunities we had in front of us, that we could guide to 15%-20% growth, and that we could incrementally drive that growth while also demonstrating operational leverage incrementally year to year over four. So that was the overarching landscape. In terms of how we would achieve that, we focused on a second priority, which was market development in certain focused areas. Our history was in a marketplace we call extremities. Most of that is emergent trauma. As we would invest in that, we also focused on oncological procedures where they're planned procedures and the patient is also part of the equation. That included breast Resensation, so restoring peripheral nerve function sensation post-mastectomy as part of the reconstruction process. Secondly, we would investigate and evaluate prostate.
The third priority that we focused on was, and we were very public about in terms of how we would do so, was simply expanding footprint. The organization that the company had when I first joined was small relative to the number of service sites as well as to the number of procedures. The very simple effort was to build an organization that would allow for proper attendance and coverage of the physical sites, as well as the training that accompanies these procedures. The fourth was commercial excellence, and expressly what we were talking about there is that one of the challenges in our opportunity is not that there isn't a lot of need that we could address, it's that it's very diverse in its manifestation. So the market's very heterogeneous.
Unlike cardiology or cardiac surgery, where you have a handful of people that you need to focus on holistically, with regards to nerves, it ranges everything from a trauma surgeon who is involved, to across 20 different specialties, if I count them all. Different care pathways, different physician societies, and so on. We needed to identify and develop business models for that purpose. The next element was to drive towards standard of care. Because, as we said, it is part of our mission, there is no expectation to treat nerve injuries. To do that, we needed to drive evidence, societal advocacy, and then coverage and payment, because they are both interdependent. Finally, innovation. Invest in the future to make these procedures less technical and more adoptable.
Okay. Very helpful overview. Thanks, Mike. I do want to hit on a bunch of different topics, but I wanted to start on breast reconstruction because we have seen some really significant growth acceleration there. I think it was over 50% in 2Q, and that accelerated to over 60% year-over-year growth in 3Q. It seems like momentum is building. I guess, can you talk about what you are seeing in that market and what is driving that meaningful acceleration?
Certainly. A number of basic factors consistent with what I just shared. Number one was we have expanded the physical footprint of the sales organization. About two and a half years ago, we had about 10 people. Today, we have 31 people. Ultimately, our target is to get to 60 people, which would give us a ratio of one representative to 20 accounts, which is the total physical account TAM in terms of service sites. These individuals are crucial because they are the ones who obviously make the calls, they, on a consultative basis, develop awareness of the opportunities to restore sensation, and they help conduct and arrange all the logistics associated with the training. Because the training involves both the oncological surgeon as well as a plastic surgeon who does the actual nerve repair, and they work as a team.
In order to bring this forward, you need to have a sales force. We very simply, we have expanded that. The value proposition is quite powerful for these procedures, in particular for breasts, because you are introducing an opportunity to mitigate the consequence of a cancer surgery, which leaves you without any feeling. As part of the reconstruction process, what we are offering here is another step, not just aesthetically, but functionally, to restore that patient's level of peripheral nerve function. As we train surgeons and as they adopt it, what we are finding is these surgeons do not stop procedures. They continue to do so, and it becomes part of their repertoire, part of what they consider standard of care for them.
As you do one surgeon, as you might imagine, the person who sits down the hallway who has not yet been trained soon wants to do the same thing because it begs the question from an equipoise standpoint, how could you not offer this if you're doing it with one surgeon as part of your cancer repertoire in a hospital and not another? This builds on itself. This reflects in terms of same-store sales. You have one surgeon, they start doing the procedure, then another surgeon adds on to that. As this is happening, what's also happening is in the care pathway, the referring physicians are now very strongly moving their patients towards those individuals.
Within a community in a metropolitan area, once you get one center going, then the other center across the street wants to participate as well because, as you might imagine, it becomes quite difficult to, as part of your hospital services, to do these procedures and not offer the chance to do a complete reconstruction. Overlaying all of this is coverage and reimbursement has advanced over those years. You put this all together, then the whole process now is much more efficient and effective in terms of being indicated for treatment and then offering the treatment. Those barriers are come down. Physicians are less reticent about adopting because they know that's out of the way. All this is building on itself, and ergo, why we have high growth. Expect to see that for years to come.
Okay. That kind of leads to the next question. I was going to ask about how you think about growth runways. Even in the U.S., where do you estimate we are in terms of penetration as we exit this year? Is OUS an addressable opportunity as well at some point?
I'll start with the first question.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
